.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Deloitte
Colorcon
McKesson
Cantor Fitzgerald
Federal Trade Commission
Johnson and Johnson
UBS
Daiichi Sankyo
Boehringer Ingelheim

Generated: December 15, 2017

DrugPatentWatch Database Preview

SANDIMMUNE Drug Profile

« Back to Dashboard

When do Sandimmune patents expire, and when can generic versions of Sandimmune launch?

Sandimmune is a drug marketed by Novartis and is included in three NDAs.

The generic ingredient in SANDIMMUNE is cyclosporine. There are seventeen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
NovartisSANDIMMUNEcyclosporineCAPSULE;ORAL050625-001Mar 2, 1990AB2RXYesNo► Subscribe► Subscribe► Subscribe
NovartisSANDIMMUNEcyclosporineINJECTABLE;INJECTION050573-001Nov 14, 1983APRXYesYes► Subscribe► Subscribe► Subscribe
NovartisSANDIMMUNEcyclosporineCAPSULE;ORAL050625-003Nov 23, 1992BXRXYesNo► Subscribe► Subscribe► Subscribe
NovartisSANDIMMUNEcyclosporineCAPSULE;ORAL050625-002Mar 2, 1990AB2RXYesYes► Subscribe► Subscribe► Subscribe
NovartisSANDIMMUNEcyclosporineSOLUTION;ORAL050574-001Nov 14, 1983AB2RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SANDIMMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
NovartisSANDIMMUNEcyclosporineCAPSULE;ORAL050625-001Mar 2, 1990► Subscribe► Subscribe
NovartisSANDIMMUNEcyclosporineCAPSULE;ORAL050625-002Mar 2, 1990► Subscribe► Subscribe
NovartisSANDIMMUNEcyclosporineCAPSULE;ORAL050625-003Nov 23, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Deloitte
Novartis
Merck
Argus Health
Citi
Cipla
McKesson
Express Scripts
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot